Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment

Plain-language summary

This study investigates whether measuring tumor DNA in the blood (ctDNA) can predict how breast cancer responds to chemotherapy given before surgery (neoadjuvant therapy). Women aged 18 and older with stage II-III HER2-positive or triple-negative breast cancer planned for neoadjuvant chemotherapy can take part. It has no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Gene Solutions

Start date

9/16/2023

Estimated completion

12/31/2025

Countries

Indonesia, Vietnam

Related genes

Locations

• Jakarta, Indonesia
• Ho Chi Minh City, Vietnam
• Ho Chi Minh City, Vietnam

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Female,18 years old and older,
* Are diagnosed with stage II-III HER2+/Triple Negative breast cancer and indicated for neoadjuvant chemotherapy,
* FFPE sample is available at the time of diagnosis and operation,
* Are voluntary to participate in the study.

Exclusion Criteria:

* Recurrent breast cancer,
* Other cancer metastasis to the breast,
* Have been or are being treated for cancer,
* Patients did not agree to participate in the studies.